← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. PAHC
  3. P/E History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

PAHC logoPhibro Animal Health Corporation (PAHC) P/E Ratio History

Historical price-to-earnings valuation from 2014 to 2026

Current P/E
36.3
Fair Value
5Y Avg P/E
37.1
-2% vs avg
PE Percentile
80%
High
PEG Ratio
4.85
Expensive
TTM EPS$2.25
Price$43.16
5Y PE Range11.6 - 286.2
Earnings Yield2.76%

Loading P/E history...

PAHC Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
36.3vs37.1
-2%
In Line with History
vs. Healthcare
36.3vs22.3
+62%
Above Sector
vs. S&P 500
36.3vs25.1
+44%
Above Market
PEG Analysis
4.85
P/E ÷ EPS Growth
PEG > 2 = Expensive
Based on 1883% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of May 8, 2026, Phibro Animal Health Corporation (PAHC) trades at a price-to-earnings ratio of 36.3x, with a stock price of $43.16 and trailing twelve-month earnings per share of $2.25.

The current P/E is roughly in line with its 5-year average of 37.1x. Over the past five years, PAHC's P/E has ranged from a low of 11.6x to a high of 286.2x, placing the current valuation at the 80th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.3x, PAHC trades at a 62% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.

The PEG ratio of 4.85 (P/E divided by 1883% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, PAHC commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PAHC DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

PAHC P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ZTS logoZTSZoetis Inc.
$37B14.51.21+10%
IDXX logoIDXXIDEXX Laboratories, Inc.
$45B43.73.06+23%
TSN logoTSNTyson Foods, Inc.
$24B49.9--40%
HRL logoHRLHormel Foods Corporation
$11B23.8--41%
PPC logoPPCPilgrim's Pride Corporation
$7B6.70.11Best-1%
CAG logoCAGConagra Brands, Inc.
$7B6.0Lowest0.85+0%
DE logoDEDeere & Company
$157B31.41.92+0%
CTVA logoCTVACorteva, Inc.
$53B49.44.14+23%Best

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

PAHC Historical P/E Data (2014–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2026 Q2Wed Dec 31 2025 00:00:00 GM$37.36$2.2516.6x-78%
FY2026 Q1$40.46$1.6624.4x-68%
FY2025 Q4Mon Jun 30 2025 00:00:00 GM$25.54$1.1821.6x-72%
FY2025 Q3Mon Mar 31 2025 00:00:00 GM$21.36$0.7827.4x-64%
FY2025 Q2$21.00$0.4843.9x-43%
FY2025 Q1Mon Sep 30 2024 00:00:00 GM$22.52$0.4352.5x-32%
FY2024 Q4Sun Jun 30 2024 00:00:00 GM$16.77$0.06286.2x+273%
FY2024 Q3Sun Mar 31 2024 00:00:00 GM$12.93$0.3240.4x-47%
FY2024 Q2Sun Dec 31 2023 00:00:00 GM$11.58$0.3632.2x-58%
FY2024 Q1Sat Sep 30 2023 00:00:00 GM$12.77$0.5125.0x-67%
FY2023 Q4Fri Jun 30 2023 00:00:00 GM$13.70$0.8116.9x-78%
FY2023 Q3Fri Mar 31 2023 00:00:00 GM$15.32$0.7121.6x-72%

Average P/E for displayed period: 76.7x

See PAHC's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is PAHC Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare PAHC vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

PAHC — Frequently Asked Questions

Quick answers to the most common questions about buying PAHC stock.

Is PAHC stock overvalued or undervalued?

PAHC trades at 36.3x P/E, near its 5-year average of 37.1x. The 80th percentile ranking places valuation within normal historical bounds.

How does PAHC's valuation compare to peers?

Phibro Animal Health Corporation P/E of 36.3x compares to sector median of 22.3x. The premium reflects expected growth above peers.

What is PAHC's PEG ratio?

PAHC PEG ratio is 4.85. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2014-2026.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

PAHC P/E Ratio History (2014–2026)

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.